Last updated: August 1, 2026
Granisetron is a mature 5-HT3 receptor antagonist used mainly to prevent chemotherapy-induced nausea and vomiting (CINV), with additional use in radiation-induced nausea and vomiting and postoperative nausea and vomiting. The product has limited clinical-development momentum because ondansetron, palonosetron and netupitant/palonosetron combinations cover much of the same market. Commercial value is concentrated in low-cost generic oral and injectable products, the Sancuso transdermal patch, and Sustol extended-release injection.
The main growth opportunities are long-duration antiemetic delivery, oncology supportive-care protocols, hospital injectable demand and selected emerging markets. The main constraints are generic price erosion, mature clinical evidence, broad substitution and limited patent protection.
What is granisetron and how is it used?
Granisetron selectively blocks serotonin 5-HT3 receptors involved in nausea and vomiting after chemotherapy, radiotherapy and surgery. It does not treat the underlying cancer or provide broad antiemetic coverage across all vomiting pathways.
| Attribute |
Granisetron profile |
| Active ingredient |
Granisetron hydrochloride |
| Drug class |
5-HT3 receptor antagonist |
| Main indications |
CINV; radiation-induced nausea and vomiting; postoperative nausea and vomiting in selected jurisdictions |
| Principal dosage forms |
Oral tablet, oral solution, intravenous injection, transdermal patch, extended-release subcutaneous injection |
| Major branded products |
Kytril, Sancuso, Sustol |
| Key manufacturers |
Roche historically developed Kytril; Kyowa Kirin commercialized Sancuso in several markets; Heron Therapeutics developed Sustol |
| FDA status |
Multiple approved products and generic versions |
| Biosimilar exposure |
None, because granisetron is a chemically synthesized small molecule |
| Primary competitors |
Ondansetron, palonosetron, dolasetron, fosaprepitant/aprepitant combinations and fixed-dose netupitant/palonosetron |
FDA labeling identifies granisetron as an antiemetic for prevention of nausea and vomiting associated with emetogenic cancer therapy. Sancuso provides transdermal delivery for patients receiving moderately emetogenic chemotherapy for up to five consecutive days. Sustol is an extended-release subcutaneous formulation for prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy and anthracycline-plus-cyclophosphamide regimens (FDA, 2016; FDA, 2023).
What is the current clinical-trial status of granisetron?
Granisetron has no comparable late-stage standalone development program to those associated with new antiemetic mechanisms. Public clinical research has shifted toward formulation studies, combinations, pediatric use, procedural nausea, postoperative nausea and vomiting, and supportive-care protocols.
Clinical-trial activity by development area
| Area |
Development status |
Commercial implication |
| Oral granisetron for CINV |
Established standard; new pivotal trials are unlikely |
Generic price competition |
| Intravenous granisetron |
Established hospital product |
Demand follows chemotherapy volume and formulary decisions |
| Transdermal granisetron |
Commercially differentiated |
Value depends on adherence, access and patch reimbursement |
| Extended-release granisetron |
Approved product with differentiated dosing |
Potential reduction in administration burden |
| Pediatric oncology |
Continued evidence generation and protocol use |
Supports institutional demand but not major exclusivity |
| Postoperative nausea and vomiting |
Broad clinical literature and off-label use |
Competes heavily with ondansetron |
| Combination antiemesis |
Used with dexamethasone, NK1 antagonists and olanzapine |
Granisetron is one component of a broader regimen |
| Novel mechanisms |
Research focus has moved toward NK1, dopamine, neurokinin and multimodal approaches |
Limits long-term standalone growth |
ClinicalTrials.gov records should be interpreted carefully because many studies evaluate granisetron as a background antiemetic rather than as the primary investigational intervention. In oncology, granisetron is commonly used in institutional regimens with dexamethasone, an NK1 antagonist and, for selected high-risk patients, olanzapine. Current treatment guidelines generally prioritize regimen-based antiemetic prophylaxis rather than selection of one 5-HT3 antagonist in isolation (National Comprehensive Cancer Network, 2024; Hesketh et al., 2020).
How does granisetron compare with ondansetron and palonosetron?
Granisetron competes on price, familiarity and formulation flexibility. Palonosetron has a longer half-life and stronger positioning in delayed CINV. Ondansetron has the broadest generic availability and extensive hospital adoption.
| Factor |
Granisetron |
Ondansetron |
Palonosetron |
| Market maturity |
Mature |
Very mature |
Mature but more differentiated |
| Half-life |
Approximately 9 hours |
Approximately 3-6 hours |
Approximately 40 hours |
| Generic competition |
Extensive |
Extensive |
Extensive, with branded and generic products |
| Transdermal option |
Yes, Sancuso |
No widely used FDA-approved patch |
No |
| Extended-release option |
Yes, Sustol |
No equivalent long-acting injection in common use |
Long-acting intravenous product |
| Main commercial advantage |
Delivery options and established efficacy |
Low cost and availability |
Delayed-CINV coverage and convenient dosing |
| Main weakness |
Limited differentiation in standard oral and IV forms |
Shorter duration |
Higher acquisition cost than basic generics |
Palonosetron's long half-life gives it a competitive advantage in delayed nausea and vomiting, while granisetron's patch and extended-release injection create differentiated niches. Standard oral and IV granisetron products remain vulnerable to substitution by ondansetron and other generic 5-HT3 antagonists.
What is the FDA regulatory and Orange Book status of granisetron?
Granisetron's original U.S. product, Kytril, was approved in the 1990s. Its core small-molecule patent and regulatory exclusivity have expired. FDA-approved generic granisetron products are available in oral and injectable forms, and the active ingredient does not have a current U.S. regulatory exclusivity profile comparable to a recently approved drug.
Sancuso was approved in 2008 as a transdermal patch. Sustol was approved in 2016 as an extended-release subcutaneous injection. Product-specific patents may have protected aspects of the patch, delivery system, formulation or manufacturing process after core granisetron composition-of-matter protection ended. Those protections do not restore exclusivity to the active ingredient itself (FDA, 2008; FDA, 2016).
What patents protect granisetron products?
The commercial patent analysis differs by product:
- Core granisetron active-ingredient protection is expired.
- Oral and conventional injectable products face generic competition.
- Sancuso protection has historically focused on transdermal delivery, patch construction, adhesive systems, drug loading and release characteristics.
- Sustol protection has focused on extended-release formulation, depot delivery, administration and manufacturing features.
- Method-of-use claims may cover prevention of CINV in defined chemotherapy settings, but their practical value is limited when the same indication is clinically established and generic products are available.
- Patent term adjustments, terminal disclaimers, continuations and jurisdiction-specific expiry dates must be reviewed at the individual patent-family level before a freedom-to-operate or litigation decision.
The U.S. Orange Book should be checked by product and applicant rather than by active ingredient alone. A patent listed against Sancuso or Sustol would not necessarily block a conventional granisetron tablet or injection. Conversely, a generic developer targeting a long-acting formulation would face a different patent and regulatory analysis from one filing an abbreviated new drug application for immediate-release granisetron.
Are there Paragraph IV challenges or generic launch risks?
Generic launch risk is high for immediate-release oral and conventional injectable granisetron because the products are old, clinically familiar and commercially substitutable. Paragraph IV litigation is less strategically important for the basic active ingredient than for product-specific delivery systems.
| Product category |
Generic risk |
Likely launch pathway |
| Immediate-release tablets |
High |
ANDA; bioequivalence and dosage-form requirements |
| Conventional IV injection |
High |
ANDA, subject to formulation and injectable-product requirements |
| Oral solution |
High to moderate |
ANDA with product-specific chemistry and bioequivalence work |
| Transdermal patch |
Moderate |
Complex generic or 505(b)(2) strategy, depending on formulation and delivery differences |
| Extended-release subcutaneous injection |
Lower than tablets, but not low |
505(b)(2), complex generic or product-specific development |
| New combination regimen |
Depends on claims |
Combination-product and clinical-evidence requirements |
A Paragraph IV filing against a listed patent could create a 30-month stay under the Hatch-Waxman framework if statutory conditions are met. The risk is greatest when a challenger targets a commercially valuable formulation and the listed patents have substantial remaining term. For conventional granisetron, the primary commercial risk is ordinary generic substitution rather than a new wave of patent litigation.
What patent litigation and settlement agreements affect granisetron?
Granisetron's central patent dispute cycle is largely historical. The drug's market has operated for years under generic competition, and no widely recognized current U.S. litigation campaign is comparable to active patent disputes involving recently launched oncology drugs.
For Sancuso and Sustol, litigation risk can arise from:
- Patent listings covering transdermal or depot delivery.
- ANDA certifications challenging formulation or method-of-use patents.
- 505(b)(2) applications relying on listed-drug safety and efficacy data.
- Royalty-bearing settlements that delay or condition entry.
- Manufacturing patents covering microspheres, depot formation, adhesive layers or release kinetics.
A legal review should separate patents listed in the Orange Book from unlisted process patents, trade secrets and contractual restrictions. Unlisted manufacturing know-how can remain commercially relevant after public patent expiry, particularly for long-acting injectable products.
What is the granisetron market size and five-year projection?
Public market reports often combine granisetron with the broader 5-HT3 antagonist or antiemetic market, producing inconsistent estimates. A defensible projection is therefore better expressed as a scenario model rather than a single market-size claim.
Base-case market outlook, 2024-2029
| Segment |
2024 direction |
2029 base-case direction |
| Oral generic granisetron |
Declining or flat revenue |
Continued price pressure |
| IV hospital granisetron |
Stable to modest growth in unit volume |
Low-single-digit unit growth, limited revenue growth |
| Sancuso |
Niche, reimbursement-sensitive |
Stable to modest growth if adherence benefits are demonstrated |
| Sustol |
Small specialty segment |
Growth possible from long-acting CINV protocols |
| Emerging markets |
Volume growth with low average selling prices |
Positive units, constrained revenue |
| Total granisetron value |
Mature and broadly stable |
Flat to low-single-digit annual growth in nominal revenue |
The base case assumes oncology incidence and chemotherapy utilization grow modestly, but generic erosion offsets much of the volume benefit. A reasonable strategic planning range is:
- Bear case: annual revenue decline of 3% to 6%.
- Base case: annual revenue growth of 0% to 3%.
- Bull case: annual revenue growth of 4% to 7%, driven by long-acting formulations, improved access and stronger adoption in emerging markets.
These ranges apply to the granisetron product category, not to a single manufacturer's sales. The commercial trajectory for an individual product can differ sharply based on reimbursement, hospital contracting, manufacturing reliability and patent position.
Which companies are positioned in the granisetron market?
The competitive field includes generic pharmaceutical companies, specialty oncology manufacturers and regional distributors.
Key commercial groups
- Heron Therapeutics: Sustol and specialty oncology commercialization.
- Kyowa Kirin and affiliated commercial partners: Sancuso in selected markets.
- Generic manufacturers: suppliers of granisetron tablets, oral solutions and injections.
- Hospital injectable companies: compete through purchasing contracts, shortages, supply reliability and bundled portfolios.
- Oncology-supportive-care companies: compete indirectly through palonosetron, aprepitant, fosaprepitant, netupitant/palonosetron and olanzapine-based regimens.
Licensing and distribution arrangements are more important for Sancuso and Sustol than for generic granisetron. The commercial value of a deal depends on geographic rights, reimbursement responsibility, manufacturing obligations and whether the agreement covers only granisetron or a wider oncology-supportive-care portfolio.
What are the main manufacturing and intellectual-property barriers?
Immediate-release granisetron has limited manufacturing barriers. The active ingredient is established, and multiple suppliers can manufacture standard dosage forms subject to regulatory quality requirements.
The barriers increase for differentiated delivery systems:
- Transdermal products require control of adhesion, drug flux, skin permeation and dose uniformity.
- Extended-release injections require reproducible depot formation, release kinetics, sterility and syringe or vial compatibility.
- Injectable manufacturing is exposed to fill-finish capacity, particulate control and shortage risk.
- Complex formulations may require more extensive comparative pharmacokinetic and clinical evidence than conventional tablets.
- Process know-how can remain valuable even when composition patents have expired.
These barriers support niche pricing but do not create a durable monopoly if competing formulations can demonstrate equivalent exposure, safety and clinical performance.
What generic launch scenarios exist for granisetron?
The most probable launch scenarios are:
- Immediate-release oral or injectable generic entry, with rapid price erosion.
- A complex generic or 505(b)(2) entrant targeting transdermal granisetron.
- A long-acting injectable competitor seeking to differentiate through dosing interval or administration setting.
- Regional launches in markets with expanding chemotherapy access.
- Hospital-contracting competition based on supply security rather than clinical differentiation.
A new conventional granisetron entrant would face low regulatory novelty but weak pricing power. A differentiated delivery entrant would face higher development costs, formulation patents and a smaller addressable market.
Key Takeaways
- Granisetron is a mature generic 5-HT3 antagonist with established use in CINV.
- Core active-ingredient exclusivity has expired, and conventional products face high generic risk.
- Sancuso and Sustol retain the main product-level differentiation through transdermal and extended-release delivery.
- Clinical research is concentrated in combinations, pediatric care, postoperative nausea and formulation strategies rather than new standalone indications.
- Palonosetron competes more effectively in delayed CINV; ondansetron remains the main low-cost substitute.
- The category's likely five-year revenue performance is flat to low-single-digit growth, with unit growth offset by price erosion.
- No biosimilar pathway applies because granisetron is a small molecule.
- The strongest remaining commercial barriers are formulation complexity, injectable manufacturing, reimbursement and supply reliability.
FAQs
Is granisetron still under patent?
The core granisetron active ingredient is no longer protected by meaningful U.S. composition-of-matter exclusivity. Product-specific patents may have covered Sancuso or Sustol delivery and formulation technologies.
Can a generic company launch granisetron without clinical trials?
For conventional products, an ANDA may rely on reference-product safety and efficacy data, subject to bioequivalence and product-specific requirements. Complex transdermal and extended-release products may require a different regulatory strategy.
Is granisetron stronger than ondansetron?
Neither drug is universally superior. Granisetron offers differentiated patch and extended-release options, while ondansetron has broader generic availability and lower cost.
Does granisetron have biosimilar competition?
No. Biosimilars apply to biologic products. Granisetron is a chemically synthesized small molecule and competes through generic-drug pathways.
Which granisetron formulation has the best commercial outlook?
Long-acting formulations have the strongest differentiation potential, but immediate-release tablets and injections have the largest established volume. Commercial success depends on reimbursement, contracting, manufacturing reliability and evidence of reduced administration burden.
References
- U.S. Food and Drug Administration. (2008). Sancuso (granisetron transdermal system) prescribing information.
- U.S. Food and Drug Administration. (2016). Sustol (granisetron) extended-release injection prescribing information.
- U.S. Food and Drug Administration. (2023). Kytril and granisetron hydrochloride prescribing information.
- National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology: Antiemesis.
- Hesketh, P. J., Kris, M. G., Basch, E., Bohlke, K., Barbour, S. Y., Clark-Snow, R. A., Danso, M. A., Dennis, K., Dupuis, L. L., Dusetzina, S. B., Engles, R. C., Feyer, P. C., Jordan, K., Noonan, K., & Somerfield, M. R. (2020). Antiemetics: ASCO guideline update. Journal of Clinical Oncology, 38(24), 2782-2797.
- ClinicalTrials.gov. (2024). Granisetron clinical studies database. U.S. National Library of Medicine.
